HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MEDI2070

targets interleukin 23 for treatment of gastrointestinal disease

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Danese, Silvio: 2 articles (12/2023 - 07/2017)
2.	Sands, Bruce E: 2 articles (12/2023 - 07/2017)
3.	Beaton, Andrew: 1 article (12/2023)
4.	Duncan, Elizabeth A: 1 article (12/2023)
5.	Mercier, Anne-Kristina: 1 article (12/2023)
6.	Neisen, Jessica: 1 article (12/2023)
7.	Seth, Henrik: 1 article (12/2023)
8.	Zetterstrand, Sofia: 1 article (12/2023)
9.	Chen, Jingjing: 1 article (07/2017)
10.	Drappa, Jörn: 1 article (07/2017)

Related Diseases

1.

Crohn Disease (Crohn's Disease)

07/01/2017 - "In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necrosis factor antagonists, 8 and 24 weeks of treatment with MEDI2070 were associated with clinical improvement. "
07/01/2017 - "Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study."
12/20/2023 - "Short-term efficacy and safety of brazikumab (MEDI2070), a human monoclonal antibody and anti-p19 subunit inhibitor of interleukin-23, was demonstrated in a phase 2a trial in patients with moderate-to-severe active Crohn's disease (CD). "
07/01/2017 - "MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). "

Related Drugs and Biologics

1.	Interleukin-23 (Interleukin 23)
2.	Monoclonal Antibodies
3.	Tumor Necrosis Factor Inhibitors
4.	Cytokines